|
1
|
Gill J, Ahluwalia MK, Geller D and Gorlick
R: New targets and approaches in osteosarcoma. Pharmacol Ther.
137:89–99. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ta HT, Dass CR, Choong PF and Dunstan DE:
Osteosarcoma treatment: State of the art. Cancer Metastasis Rev.
28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen D, Zhang YJ, Zhu KW and Wang WC: A
systematic review of vascular endothelial growth factor expression
as a biomarker of prognosis in patients with osteosarcoma. Tumour
Biol. 34:1895–1899. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fu HL, Shao L, Wang Q, Jia T, Li M and
Yang DP: A systematic review of p53 as a biomarker of survival in
patients with osteosarcoma. Tumour Biol. 34:3817–3821. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hu F, Shang XF, Wang W, Jiang W, Fang C,
Tan D and Zhou HC: High-level expression of periostin is
significantly correlated with tumour angiogenesis and poor
prognosis in osteosarcoma. Int J Exp Pathol. 97:86–92. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang S, Ren Z, Han X, Yang J, Shan L, Li
L, Wang B, Zhang Q, Mu T, Chen K, et al: PLA2G16 expression in
human osteosarcoma is associated with pulmonary metastasis and poor
prognosis. PloS One. 10:e01272362015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu Y, Wu Y, Gu S, Sun Z, Rui Y, Wang J,
Lu Y, Li H, Xu K and Sheng P: Prognostic role of CD44 expression in
osteosarcoma: Evidence from six studies. Diagn Pathol. 9:1402014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yao D, Cai GH, Chen J, Ling R, Wu SX and
Li YP: Prognostic value of p53 alterations in human osteosarcoma: A
meta analysis. Int J Clin Exp Pathol. 7:6725–6733. 2014.PubMed/NCBI
|
|
9
|
Liu Y, Wu Y, Gu S, Sun Z, Rui Y, Wang J,
Lu Y, Li H, Xu K and Sheng P: Prognostic role of CD44 expression in
osteosarcoma: Evidence from six studies. Diagn Pathol. 9:1402014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kumar MS, Lu J, Mercer KL, Golub TR and
Jacks T: Impaired microRNA processing enhances cellular
transformation and tumorigenesis. Nat Genet. 39:673–677. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan W, Wang H, Jianwei R and Ye Z:
MicroRNA-27a promotes proliferation, migration and invasion by
targeting MAP2K4 in human osteosarcoma cells. Cell Physiol Biochem.
33:402–412. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao F, Lv J, Gan H, Li Y, Wang R, Zhang
H, Wu Q and Chen Y: MiRNA profile of osteosarcoma with CD117 and
stro-1 expression: miR-1247 functions as an onco-miRNA by targeting
MAP3K9. Int J Clin Exp Pathol. 8:1451–1458. 2015.PubMed/NCBI
|
|
14
|
Jin J, Cai L, Liu ZM and Zhou XS:
miRNA-218 inhibits osteosarcoma cell migration and invasion by
down-regulating of TIAM1, MMP2 and MMP9. Asian Pac J Cancer Prev.
14:3681–3684. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun XH, Geng XL, Zhang J and Zhang C:
miRNA-646 suppresses osteosarcoma cell metastasis by downregulating
fibroblast growth factor 2 (FGF2). Tumour Biol. 36:2127–2134. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tian X, Zhang J, Yan L, Dong JM and Guo Q:
MiRNA-15a inhibits proliferation, migration and invasion by
targeting TNFAIP1 in human osteosarcoma cells. Int J Clin Exp
Pathol. 8:6442–6449. 2015.PubMed/NCBI
|
|
17
|
Cao J, Cai J, Huang D, Han Q, Yang Q, Li
T, Ding H and Wang Z: miR-335 represents an invasion suppressor
gene in ovarian cancer by targeting Bcl-w. Oncol Rep. 30:701–706.
2013.PubMed/NCBI
|
|
18
|
Gao L, Yang Y, Xu H, Liu R, Li D, Hong H,
Qin M and Wang Y: MiR-335 functions as a tumor suppressor in
pancreatic cancer by targeting OCT4. Tumour Biol. 35:8309–8318.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao Y, Zeng F, Wu JY, Li HY, Fan JJ, Mai
L, Zhang J, Ma DM, Li Y and Song FZ: MiR-335 inhibits migration of
breast cancer cells through targeting oncoprotein c-Met. Tumour
Biol. 36:2875–2883. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gong M, Ma J, Guillemette R, Zhou M, Yang
Y, Yang Y, Hock JM and Yu X: miR-335 inhibits small cell lung
cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer
Res. 12:101–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang K, Chen X, Zhan Y, Jiang W, Liu X,
Wang X and Wu B: miR-335 inhibits the proliferation and invasion of
clear cell renal cell carcinoma cells through direct suppression of
BCL-W. Tumour Biol. 36:6875–6882. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang Y, Zhao W and Fu Q: miR-335
suppresses migration and invasion by targeting ROCK1 in
osteosarcoma cells. Mol Cell Biochem. 384:105–111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cai H, Lin L, Tang M and Wang Z: Combined
microRNA-340 and ROCK1 mRNA profiling predicts tumor progression
and prognosis in pediatric osteosarcoma. Int J Mol Sci. 15:560–573.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yu L, Zhang J, Guo X, Li Z and Zhang P:
MicroRNA-224 upregulation and AKT activation synergistically
predict poor prognosis in patients with hepatocellular carcinoma.
Cancer Epidemiol. 38:408–413. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Spiessl B, Scheibe O and Wagner G: Soft
tissue sarcomas. In: International Union Against Cancer (UICC)
TNM-AtlasIllustrated Guide to the Classification of Malignant
Tumours. Springer-Verlag; Berlin: pp. 170–172
|
|
26
|
Liu P, Zhang H, Liang X, Ma H, Luan F,
Wang B, Bai F, Gao L and Ma C: HBV preS2 promotes the expression of
TAZ via miRNA-338-3p to enhance the tumorigenesis of hepatocellular
carcinoma. Oncotarget. 6:29048–29059. 2015.PubMed/NCBI
|
|
27
|
Santhi WS, Prathibha R, Charles S, Anurup
KG, Reshmi G, Ramachandran S, Jissa VT, Sebastian P and Pillai
Radhakrishna M: Oncogenic microRNAs as biomarkers of oral
tumorigenesis and minimal residual disease. Oral Oncol. 49:567–575.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu C, Zeng Q, Xu W, Jiao L, Chen Y, Zhang
Z, Wu C, Jin T, Pan A, Wei R, et al: miRNA-100 inhibits human
bladder urothelial carcinogenesis by directly targeting mTOR. Mol
Cancer Ther. 12:207–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shu M, Zhou Y, Zhu W, Zhang H, Wu S, Chen
J and Yan G: MicroRNA 335 is required for differentiation of
malignant glioma cells induced by activation of cAMP/protein kinase
A pathway. Mol Pharmacol. 81:292–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang K, Chen X, Zhan Y, Jiang W, Liu X,
Wang X and Wu B: miR-335 inhibits the proliferation and invasion of
clear cell renal cell carcinoma cells through direct suppression of
BCL-W. Tumour Biol. 36:6875–6882. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shu M, Zheng X, Wu S, Lu H, Leng T, Zhu W,
Zhou Y, Ou Y, Lin X, Lin Y, et al: Targeting oncogenic miR-335
inhibits growth and invasion of malignant astrocytoma cells. Mol
Cancer. 10:592011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shi L, Jiang D, Sun G, Wan Y, Zhang S,
Zeng Y, Pan T and Wang Z: miR-335 promotes cell proliferation by
directly targeting Rb1 in meningiomas. J Neurooncol. 110:155–162.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Schofield AV and Bernard O: Rho-associated
coiled-coil kinase (ROCK) signaling and disease. Crit Rev Biochem
Mol Biol. 48:301–316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Patel RA, Liu Y, Wang B, Li R and Sebti
SM: Identification of novel ROCK inhibitors with anti-migratory and
anti-invasive activities. Oncogene. 33:550–555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Oellers P, Schröer U, Senner V, Paulus W
and Thanos S: ROCKs are expressed in brain tumors and are required
for glioma-cell migration on myelinated axons. Glia. 57:499–509.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kamai T, Tsujii T, Arai K, Takagi K, Asami
H, Ito Y and Oshima H: Significant association of Rho/ROCK pathway
with invasion and metastasis of bladder cancer. Clin Cancer Res.
9:2632–2641. 2003.PubMed/NCBI
|
|
37
|
Akagi EM, Lavorato-Rocha AM, Bde Maia M,
Rodrigues IS, Carvalho KC, Stiepcich MM, Baiocchi G, Sato-Kuwabara
Y, Rogatto SR, Soares FA and Rocha RM: ROCK1 as a novel prognostic
marker in vulvar cancer. BMC cancer. 14:8222014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Liu X, Choy E, Hornicek FJ, Yang S, Yang
C, Harmon D, Mankin H and Duan Z: ROCK1 as a potential therapeutic
target in osteosarcoma. J Orthop Res. 29:1259–1266. 2011.
View Article : Google Scholar : PubMed/NCBI
|
